In the BioHarmony Drug Report Database

"Preview" Icon

Pomalidomide

Pomalyst, Imnovid, Pomalidomide Celgene (pomalidomide) is a small molecule pharmaceutical. Pomalidomide was first approved as Pomalyst on 2013-02-08. It is used to treat kaposi sarcoma and multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target protein cereblon. Pomalyst’s patents are valid until 2031-06-21 (FDA).

 

Trade Name

 

Imnovid, Pomalidomide Celgene
 

Common Name

 

pomalidomide
 

ChEMBL ID

 

CHEMBL43452
 

Indication

 

kaposi sarcoma, multiple myeloma
 

Drug Class

 

Thalidomide derivatives

Image (chem structure or protein)

Pomalidomide structure rendering